The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

On Monday, Cardinal Health Inc (CAH) stock saw a modest uptick, ending the day at $120.03 which represents a slight increase of $1.25 or 1.05% from the prior close of $118.78. The stock opened at $118 ...

On Monday, Fulcrum Therapeutics Inc (FULC) stock saw a modest uptick, ending the day at $3.03 which represents a slight increase of $0.02 or 0.66% from the prior close of $3.01. The stock opened at $3 ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Lexeo Therapeutics in ...

The good news from Monday’s results, according to Leerink Partners’ David Risinger, is that icotrokinra’s efficacy seems ...

CVS Health has added four new board members, including the CEO of a hedge fund that has been critical of the struggling ...

CVS Health said on Monday it added four new members to its board including hedge fund Glenview Capital's chief executive Larry Robbins as part of a standstill agreement with the activist investor. The ...

Research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Ardent Health Partners in a ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...